{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:01:38Z","timestamp":1780614098792,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41440-026-02631-7","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:54:17Z","timestamp":1776653657000},"page":"1951-1960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Sacubitril\/Allisartan versus Olmesartan on serum uric acid in Chinese patients with hypertension and hyperuricaemia"],"prefix":"10.1038","volume":"49","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Mei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2631_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/HYPERTENSIONAHA.122.17956","volume":"79","author":"C Borghi","year":"2022","unstructured":"Borghi C, Agnoletti D, Cicero AFG, Lurbe E, Virdis A. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. Hypertension. 2022;79:1927\u201336.","journal-title":"Hypertension"},{"key":"2631_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12872-021-02427-2","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Nie FQ, Huang XB, Tang WW, Hu R, Zhang WQ, et al. High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China. BMC Cardiovasc Disord. 2022;22:2.","journal-title":"BMC Cardiovasc Disord"},{"key":"2631_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125:679\u2013687.e1.","journal-title":"Am J Med"},{"key":"2631_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/atm-20-3458","volume":"9","author":"J Liu","year":"2021","unstructured":"Liu J, Chen LY, Yuan H, Huang K, Li GP, Sun NL, et al. Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study. Ann Transl Med. 2021;9:27.","journal-title":"Ann Transl Med"},{"key":"2631_CR5","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1291\/hypres.27.835","volume":"27","author":"K Nagahama","year":"2004","unstructured":"Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27:835\u201341.","journal-title":"Hypertens Res"},{"key":"2631_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/HJH.0000000000001956","volume":"37","author":"Y Huang","year":"2019","unstructured":"Huang Y, Deng Z, Se Z, Bai YJ, Yan CJ, Zhan Q, et al. Combined impact of risk factors on the subsequent development of hypertension. J Hypertens. 2019;37:696\u2013701.","journal-title":"J Hypertens"},{"key":"2631_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/01.HYP.0000150783.79172.bb","volume":"45","author":"AB Alper Jr","year":"2005","unstructured":"Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension. 2005;45:34\u201338.","journal-title":"Hypertension"},{"key":"2631_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/HJH.0b013e32813aeb6c","volume":"25","author":"S Syamala","year":"2007","unstructured":"Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007;25:1583\u20139.","journal-title":"J Hypertens"},{"key":"2631_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/jhh.2008.104","volume":"23","author":"Z Lu","year":"2009","unstructured":"Lu Z, Dong B, Wu H, Chen T, Zhang Y, Wu J, et al. Serum uric acid level in primary hypertension among Chinese nonagenarians\/centenarians. J Hum Hypertens. 2009;23:113\u201321.","journal-title":"J Hum Hypertens"},{"key":"2631_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.746886","volume":"8","author":"YH Hung","year":"2022","unstructured":"Hung YH, Huang CC, Lin LY, Chen JW. Uric acid and impairment of renal function in non-diabetic hypertensive patients. Front Med. 2022;8:746886.","journal-title":"Front Med"},{"key":"2631_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.570000","volume":"7","author":"V Visco","year":"2020","unstructured":"Visco V, Pascale AV, Virtuoso N, Mongiello F, Cinque F, Gioia R, et al. Serum uric acid and left ventricular mass in essential hypertension. Front Cardiovasc Med. 2020;7:570000.","journal-title":"Front Cardiovasc Med"},{"key":"2631_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.numecd.2021.12.009","volume":"32","author":"Y Huang","year":"2022","unstructured":"Huang Y, Chen S, Yang X, Lin Z, Yan L, Wang F, et al. Impact of serum uric acid on subclinical myocardial injury in general population. Nutr Metab Cardiovasc Dis. 2022;32:641\u20137.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2631_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1047-2797(99)00037-X","volume":"10","author":"JT Moriarity","year":"2000","unstructured":"Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) Study. Ann Epidemiol. 2000;10:136\u201343.","journal-title":"Ann Epidemiol"},{"key":"2631_CR14","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","volume":"37","author":"MJ Bos","year":"2006","unstructured":"Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke. 2006;37:1503\u20137.","journal-title":"Stroke"},{"key":"2631_CR15","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1371\/journal.pmed.0020076","volume":"2","author":"JG Wheeler","year":"2005","unstructured":"Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:e76.","journal-title":"PLoS Med"},{"key":"2631_CR16","doi-asserted-by":"publisher","first-page":"e1921618","DOI":"10.1001\/jamanetworkopen.2019.21618","volume":"3","author":"J Wei","year":"2020","unstructured":"Wei J, Galaviz KI, Kowalski AJ, Magee MJ, Haw JS, Narayan KMV, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw Open. 2020;3:e1921618.","journal-title":"JAMA Netw Open"},{"key":"2631_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543784.2021.1985464","volume":"31","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhang H, Li XJ, Mai JJ, Yang LZ, Yan J, et al. A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor neprilysin inhibitor, in healthy Chinese volunteers. Expert Opin Investig Drugs. 2022;31:977\u201385.","journal-title":"Expert Opin Investig Drugs"},{"key":"2631_CR18","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41440-023-01326-7","volume":"46","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhang W, Yan J, Ge Q, Lu XH, Chen SX, et al. Efficacy and safety of sacubitril\/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study. Hypertens Res. 2023;46:2024\u201332.","journal-title":"Hypertens Res"},{"key":"2631_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacasi.2024.06.002","volume":"4","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhang J, Yan J, Ge Q, Lu XH, Chen SX, et al. Efficacy and safety of Sacubitril\/Allisartan for the treatment of primary hypertension. JACC Asia. 2024;4:697\u2013707.","journal-title":"JACC Asia"},{"key":"2631_CR20","doi-asserted-by":"publisher","first-page":"F991","DOI":"10.1152\/ajprenal.00283.2001","volume":"282","author":"M Mazzali","year":"2002","unstructured":"Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991\u2013F997.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2631_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","volume":"71","author":"RJ Johnson","year":"2018","unstructured":"Johnson RJ, Bakris G, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018;71:851\u201365.","journal-title":"Am J Kidney Dis"},{"key":"2631_CR22","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/01.HYP.37.4.1069","volume":"37","author":"JG Wang","year":"2001","unstructured":"Wang JG, Staessen JA, Fagard RH. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 2001;37:1069\u201374.","journal-title":"Hypertension"},{"key":"2631_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MBP.0000000000000554","volume":"26","author":"D Zhang","year":"2021","unstructured":"Zhang D, Huang QF, Li Y, Wang JG. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan\/hydrochlorothiazide combination. Blood Press Monit. 2021;26:413\u20138.","journal-title":"Blood Press Monit"},{"key":"2631_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/08037051.2021.1996220","volume":"30","author":"D Zhang","year":"2021","unstructured":"Zhang D, Huang QF, Sheng CS, Li Y, Wang JG. Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers. Blood Press. 2021;30:395\u2013402.","journal-title":"Blood Press"},{"key":"2631_CR25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10517-023-05917-9","volume":"175","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Miao Z, Sun J, Xing W, Wei Y, Bai J, et al. Allisartan Isoproxil promotes uric acid excretion by interacting with intestinal urate transporters in hyperuricemic zebrafish (Danio rerio). Bull Exp Biol Med. 2023;175:638\u201343.","journal-title":"Bull Exp Biol Med"},{"key":"2631_CR26","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00004872-199917030-00017","volume":"17","author":"P Rousso","year":"1999","unstructured":"Rousso P, Buclin T, Nussberger J, D\u00e9costerd LA, Roche SD, Brunner-Ferber F, et al. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. J Hypertens. 1999;17:427\u201337.","journal-title":"J Hypertens"},{"key":"2631_CR27","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ehf2.14352","volume":"10","author":"Y Kashiwagi","year":"2023","unstructured":"Kashiwagi Y, Nagoshi T, Kimura H, Tanaka Y, Oi Y, Inoue Y, et al. Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure. ESC Heart Fail. 2023;10:1860\u201370.","journal-title":"ESC Heart Fail"},{"key":"2631_CR28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","volume":"44","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021;44:1239\u201350.","journal-title":"Hypertens Res"},{"key":"2631_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/08037051.2020.1829458","volume":"30","author":"W Zhang","year":"2021","unstructured":"Zhang W, Xu JZ, Lu XH, Li H, Wang D, Wang JG. Ambulatory blood pressure in relation to interaction between dietary sodium intake and serum uric acid in the young. Blood Press. 2021;30:60\u201366.","journal-title":"Blood Press"},{"key":"2631_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ejhf.1056","volume":"20","author":"UM Mogensen","year":"2018","unstructured":"Mogensen UM, K\u00f8ber L, Jhund PS, Desai AS, Senni M, Kristensen SL, et al. Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018;20:514\u201322.","journal-title":"Eur J Heart Fail"},{"key":"2631_CR31","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/ejhf.1984","volume":"22","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Causland F, McGrath MM, et al. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020;22:2093\u2013101.","journal-title":"Eur J Heart Fail"},{"key":"2631_CR32","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450\u201361.","journal-title":"N Engl J Med"},{"key":"2631_CR33","first-page":"4186","volume":"21","author":"M Cutolo","year":"2017","unstructured":"Cutolo M, Cimmino MA, Perez-Ruiz F. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Eur Rev Med Pharmacol Sci. 2017;21:4186\u201395.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02631-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02631-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:02:48Z","timestamp":1780610568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02631-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02631-7","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JGW reports receiving lecture and consulting fees from Novartis, Omron, Servier, and Viatris. The other authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}